Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate
An Open, Randomized, Controlled, Parallel Group, Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate Together With a Randomized Placebo Controlled Double Blind Fermagate Comparison in Hemodialysis Patients With Hyperphosphatemia
Sponsor: Ineos Healthcare Limited
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Ineos Healthcare Limited
More terminations from Ineos Healthcare Limited
A PHASE3 clinical study on Chronic Kidney Failure, this trial is terminated or withdrawn. The trial is conducted by Ineos Healthcare Limited and has accumulated 7 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Jul 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ineos Healthcare Limited
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Amiens, France , Arlington, United States , Arvada, United States , Aschaffenburg, Germany , Auckland, New Zealand , Bad König, Germany , Barcelona, Spain , Berkley, United States , Birkirkara, Malta and 93 more locations